

UAB RESEARCH CENTER OF EXCELLENCE IN ARSENICALS

Counter**ACT**




Molecular Underpinning of Vesicant Chemical Injury and MCM Development

Mohammad Athar, Ph. D.
Department of Dermatology


Introduction

- A large number of highly toxic chemicals which are used in chemical warfare or for industrial purposes pose significant threat to the environment and human health if exposed accidentally or during the terrorist attack (Homeland Security identified 200 chemicals segregated as Toxidrome)
- Arsenicals are one group of such chemicals in the category called vesicants, which were developed and weaponized during world wars I and II
- Of these, Lewisite (2-chlorovinyl-dichloroarsine) is the best-known rapid action chemical weapon given the nick name 'Dew of Death'

- **Arsenicals cause severe painful inflammation in the skin, eye and lungs**
- **Their cutaneous exposure also causes severe systemic injury often leading to lethality in humans. These include acute kidney damage, lung, liver, immune and neural injury**
- **The molecular pathogenesis of lesions caused by these chemicals remains largely undefined. Therefore, our focus is on unraveling the molecular pathogenesis of arsenicals in the skin, lung and kidney following their cutaneous exposure**
- **To develop mechanism-based effective counter-measures which can effectively block tissue damage, morbidity and lethality in animal models**



USE OF CHEMICAL WEAPONS (Estimated fatalities)



U.S. Accuses Russia of Using Chemical Weapons in Ukraine

The State Department said Russia had used chloropicrin, a poison gas widely used during World War I, against Ukrainian forces, an act that would violate a global ban signed by Moscow. Nicole Tung for The New York Times, May 2, 2024




Sezigen, S et al
Toxicol. Lett., 2019



Al Berquoni, NL et al,
Lancet, 2010


Global distribution of groundwater warfare arsenicals and arsenic




This map overlays the distribution of warfare arsenicals (existing stockpiles, land buried and offshore dumped arsenicals) with the average groundwater arsenic concentrations in different countries around the world (Podgorski et al; 2020) .

Muzaffar et al., 2023


Structures of Organic & Inorganic Arsenicals




Lewisite




Diethylchloroarsine




Arsine



Arsenic Trichloride




Diphenylchlorarsine (Clark1)
(Sneezing agent)




Diphenylcyanoarsine

Diphenylcyanoarsine (Clark 2)
(Vomiting agent)



Phenylarsine Oxide



Arsenic Trioxide

Needs for Developing Medical Countermeasures (MCMs) for Toxic Agents

- **Suitable animal models which can faithfully recapitulate the human pathogenesis of toxic chemical (more than one model) & identifying a surrogate chemical that can be used in the laboratory safety conditions**
- **Defined molecular pathogenesis of lesions caused by exposure to these chemicals with druggable molecular target(s)**
- **Defined molecular toxidrome (identifying common targets)**
- **Availability drugs that can be repurposed or novel small molecules with IP rights**

Warfare Vesicants Induce Severe Tissue Damage by Disrupting Multiple Innate Immune Regulatory Control

Translational control

Lewisite, Diphenylchlorarsine, Diphenylcyanoarsine, Diethylchlorarsine and Phenylarsine oxide

Vesicants

Epigenetic targets

Post Transcriptional regulation
(RNA binding proteins)

Percutaneous Exposure

Models

Murine & Porcine



Damage

Skin


Lung

Kidney


Inflammation

Tissue Disruption/Remodeling


Pain



Lewisite, Diphenylchlorarsine, and Diphenylcyanoarsine Induce Similar Micro-blisters and Cutaneous Injury in Mice



Lewisite-induced Cutaneous Blisters in Gottingen Minipig Skin



Effects of Arsenicals on Disruption of Tight & Adherens Junctions

Murine Model

YAP / α -Cat/
DAPI


ZO-1/YAP
/DAPI

Control

Lewi

DPCA

DPCYA



Porcine Model

YAP / α -Cat/
DAPI

YAP /ZO1/
DAPI

Control

Lewi

DPCA


DPCYA

Control

1.0mg
(Lewi)

2.0mg
(Lewi)

3.0mg
(Lewi)



Lewisite, DPCA, DPCYA Induce Severe Cutaneous Inflammation





Mice

DPCYA





DPCA

Lewi

Control



F4/80



MPO

Minipig





Control

Lewi





DPCA

DPCYA





MPO







CD163



CD11R3



CD3



Development of Arsenical Surrogate

SCIENTIFIC REPORTS

OPEN

Defining cutaneous molecular pathobiology of arsenicals using phenylarsine oxide as a prototype

Received: 09 June 2016

Accepted: 16 September 2016



Published: 11 October 2016

Ritesh K. Srivastava^{1,*}, Changzhao Li^{1,*}, Zhiping Weng¹, Anupam Agarwal², Craig A. Elmetts¹, Farrukh Afaq¹ & Mohammad Athar¹

Arsenicals are painful, inflammatory and blistering causing agents developed as chemical weapons in

Control



PAO



F4/80

Control



PAO



H & E Staining

Control


PAO




TUNEL/DAPI

Unfolded Protein Responses is Associated with Arsenicals-Induced Cutaneous Injury



Human Skin Keratinocytes





Validation in Mice Skin



Validation in Pig Skin



PQC capacity



Li C. et. al. Am J Pathol.
2016 Oct;186(10):2637-49.

Chaperone/Antioxidant Therapy

4-Phenyl Butyric Acid (4-PBA)

(FDA approved for Urea Cycle Disorders on May13, 1996)

Marketed by:

- i. Ucyglyd Pharma
- ii. Swedish Orphan International
- iii. Fyrlklovern Scandinavia

4-PBA+taurursodiol



(FDA approved for Amyotrophic Lateral Sclerosis 09/2022)

N-acetyl Cysteine (NAC)


(FDA approved for overdose toxicity of Acetaminophen on January 23, 2004)

Marketed by: Cumberland Pharma


Combination of 4-PBA+NAC is Highly Effective in Attenuating Arsenical-induced Cutaneous Injury in Mice





Combination of 4-PBA+NAC Reverses Lewisite-induced Inflammatory Phenotype in Mouse Skin



Combination of 4-PBA+NAC Reverses Lewisite-induced Alterations in Genomic Occupancy of ATF4 in Mouse Skin





Gene expression and transcription regulatory network




Lewisite
influenced
Atf4 binding

Expression of Common Genes (RNASeq) in Mouse and Porcine Models



Combination of 4-PBA+NAC is Highly Effective in Attenuating Arsenical-induced Cutaneous Injury in Minipig



Conclusions


- **4-PBA in combination with NAC provides a highly effective MCM against Lewisite and acts by attenuating ER stress and protein translation.**
- **This treatment is equally effective against other arsenicals induced vesicant injury**

Epigenetic Mechanisms Regulating Blistering, Nociception and Tissue Disruption

Hypothesis

The unifying hypothesis is to uncover the role histone hyperacetylation-dependent epigenetic regulation of multiple signaling pathways, which orchestrate the robust inflammatory and tissue damaging responses induced by arsenicals. The epigenetic reader bromodomain 4 (BRD4) as a novel, potent therapeutic target for mitigating arsenicals-induced tissue injury will be investigated.

Targeting Bromodomains: Epigenetic Readers of Lysine Acetylation




Nature Reviews Molecular Cell Biology 16, 258–264 (2015)

Transcription
of Genes in
Inflammation,
Tissue
Damage/
Remodeling


BET Bromodomain Therapeutic Activity

- Bromodomain family of proteins are involved in reading of acetylated lysine on histones DNA and facilitate the transcriptional regulation of various inflammatory and oncogenes.
- Bromodomain inhibition leads to gene expression changes that may affect pathological conditions of various inflammatory diseases.




Arsenicals-induced BRD4 targets

Arsenicals



RNA seq

BRD4 regulated targets




Confirmed BRD4 targets
by RT-PCR in Skin


a-Lewi, b-DPCA
c-PAO, d-DPCyA

BRD4-regulated Transcription of Genes by Various Arsenicals in Multiple Organs


Skin




Solute Carrier







Lewisite






Arsenicals Induce BRD4 Expression and Lysine Hyperacetylation of Histones



BRD4 Inhibitor, JQ1 Block PAO-induced Histone Hyperacetylation and Inflammation in Mouse Skin




Lewisite and other Arsenicals Induce Hyperacetylation of H3 & H4 Histones in Porcine Skin








Necroptosis Regulating Signaling in Tissue Inflammation and Damage

Murine Skin

Porcine Skin



RT-PCR confirmation



Necrosis in Arsenicals- treated Skin

Pharmacology and Tox Data for Dual BRD4-RIPK3 Inhibitor





Table 1: PK parameters of SRI-43887 in mice plasma

Parameters	SRI-43887		
Route	IP	IV	PO
Dose (mg/kg)	10	1	5
t _{1/2} (h)	3.63	1.70	2.85
T _{max} (h)	0.25	----	0.50
C _{max} (ng/mL)	2937	----	225
AUC _{last} (h*ng/mL)	2010	284	361
% F	----	----	28.5


Assay	SRI-43887 (HCl salt)
Mini-Ames	Negative
hERG	IC ₅₀ = 13.35 µM (low inhibition)
Cyp Inhibition	CYP1A2, CYP2A6, CYP2C19, CYP2D6, CYP2E1 >50 µM; CYP2B6 = 40.92 µM; CYP2C8 = 14.93 µM; CYP2C9 = 42.27 µM; CYP3A4/5_MIDAZOLAM = 11.39 µM; CYP3A4/5_TESTOSTERONE = 36.52 µM
Maximum Tolerated Dose	IP Dosing: 1, 10, 30 mg/kg Vehicle: DMSO/PEG400/Water (5/30/65) No abnormality was observed at 1, 10, 30 mg/kg
Kinase Panel (39 kinases)	10 µM: ≥80% inhibition against 14 kinases
Protein binding	94.89%
Drug SafetyScreen44	10 µM: ≥50% inhibition (inh.) in 6 primary assays: Phosphodiesterase PDE4D2 (58% inh.); Cyclooxygenase COX-1 (71% inh.); Cholecystokinin CCK ₁ (CCK _A) (84% inh.);

Effects of BRD4 inhibitors on Lewisite-induced Skin Injury in Murine Model

Treatment protocol



Lewisite (L)




CPI0610




SRI43887




ABBV744





Control




Lewisite





Lewisite+
SRI43887



Effects of BRD4 inhibitors on Lewisite-induced Skin Injury in Porcine Model



Model of cutaneous arsenical-induced Acute Lung Injury: Utilizing PAO as a surrogate for Lewisite




Gas Exchange


PAO:
Phenylarsine Oxide

BRD4i Mitigates Cellular Injury & Reverses ALI in Mice Challenged with Cutaneous PAO


Protein Leak







Arterial blood gas



HMGB1 in BALF




BRD4i CPI-0610 Reverses DLI in Mice Challenged with Cutaneous PAO





BRD4i CPI-0610 Reduces Arsenical-induced AKI


Serum NGAL




HO-1 IHC




Serum NGAL




Urine NGAL



Urine KIM-1



PAO, 24 hours



PIPELINE of SMALL MOLECULES under DEVELOPMENT as MCMs AGAINST ARSENICALS

	AGENTS	TARGET	STAGE OF DEVELOPMENT
1.	N-acetyl cysteine (NAC)	Reactive oxygen species (ROS)	Efficacy completed & formulation in progress
2.	4-phenyl butyric acid (4-PBA)	Unfolded Proteins	Efficacy completed & formulation in progress
3.	NAC + 4-PBA	ROS + Unfolded proteins	Efficacy completed & formulation in progress
4.	SRI-44412	BET Bromodomain	Efficacy studies completed
5.	SRI-43887 dual inhibitor	Dual -BRD4 + RIPK3	Efficacy studies completed
	SRI-44078	RIPK3	Efficacy studies completed
	CPI-0610/ABBV-744/ JQ1/ OTX0515/ ZL0420	BET Bromodomain	Efficacy studies completed
	ISRIB/Salubrinal	eIF2 α and stress Granules	Efficacy studies completed
	Necrosulfonamide	MLKL	Efficacy studies completed
	Nordihydroguaiaretic acid (NDGA)	Lipoxygenase (LOX), p300	Efficacy studies completed
11.	H-151/C-176	Stimulator of interferon genes (STING)	In progress
12.	G140/RU.521	dsDNA sensor, cGAS	In progress
13.	8-Azaadenosine	dsRNA sensor-ADAR1 inhibitor	In progress

Summary

- Established murine and porcine models of skin exposures to single high dose of vesicants that recapitulate human pathobiology of cutaneous and systemic injury
- Developed molecular toxidrome of blistering agents with an objective to develop single MCM for multiple toxic chemicals
- Identified additional multiple druggable molecular targets and assessed their potential utility in MCM development

Summary (continued.)

- Two distinct MCMs have advanced with remarkable efficacy in two animal models against lewisite and other vesicants with defined molecular targets and mechanisms of action
- Developed impressive pipeline of MCMs which are at different stages of preclinical development and include novel (with IP rights) and repurposed drugs

Conclusion

Our translational approach is “Mechanism to Clinic”. In this regard, we are also identifying surrogate disease with similar molecular pathogenesis for FDA approval and stock piling.

Thank You

Grant Support

CounterACT Program of NIH

U54 ES030246

U01 AR078544



Acknowledgements

Project -01 Team



Collaborators


Education Core Team



Project-03 Team



Project-02 Team



Drug Discovery Team



Dr. Antony's Lab



Acknowledgment



425 Volker Boulevard
Kansas City, Missouri
64110-2241
(816) 753-7600



MRIGlobal Team

<http://www.mriglobal.org>